Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | pyrimidinergic receptor P2Y, G-protein coupled, 6 | Starlite/ChEMBL | References |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 11 | Starlite/ChEMBL | References |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 14 | Starlite/ChEMBL | References |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 2 | Starlite/ChEMBL | References |
Homo sapiens | PPAN-P2RY11 readthrough | References | |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | purinergic receptor P2Y, G-protein coupled, 1 | 373 aa | 393 aa | 17.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | brix domain containing protein | 0.0075 | 0.5 | 0.5 |
Plasmodium falciparum | BRIX domain, putative | 0.0075 | 0.5 | 0.5 |
Trypanosoma cruzi | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0075 | 0.5 | 0.5 |
Toxoplasma gondii | brix domain-containing protein | 0.0075 | 0.5 | 0.5 |
Trypanosoma brucei | brix domain containing protein, putative | 0.0075 | 0.5 | 0.5 |
Loa Loa (eye worm) | brix domain-containing protein | 0.0075 | 0.5 | 0.5 |
Giardia lamblia | Peter pan protein | 0.0075 | 0.5 | 0.5 |
Trichomonas vaginalis | ssf, putative | 0.0075 | 0.5 | 0.5 |
Echinococcus granulosus | peter pan | 0.0075 | 0.5 | 0.5 |
Echinococcus multilocularis | peter pan | 0.0075 | 0.5 | 0.5 |
Schistosoma mansoni | peter pan-related | 0.0075 | 0.5 | 0.5 |
Trypanosoma cruzi | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Schistosoma mansoni | peter pan-related | 0.0075 | 0.5 | 0.5 |
Leishmania major | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Onchocerca volvulus | Peter pan protein homolog | 0.0075 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 16 nM | Displacement of [beta-33P]-2MeS-ADP from human P2Y1 receptor transfected in HEK293 cells assessed as residual [beta-33P] bound to plate after 1 hr by scintillation counting analysis | ChEMBL. | 23368907 |
Ki (binding) | = 3300 nM | Inhibition of human P2Y14 receptor | ChEMBL. | 23368907 |
Ki (binding) | = 6400 nM | Inhibition of human P2Y2 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 15000 nM | Inhibition of human P2Y11 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 15000 nM | Inhibition of human P2Y6 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 70000 nM | Displacement of [beta-33P]-2MeS-ADP from human P2Y12 receptor transfected in HEK293 cells assessed as [beta-33P] bound to cells after 1 hr by scintillation counting analysis | ChEMBL. | 23368907 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.